Pharmacogenomics · 2025
ADIPOQ genotypes and haplotypes, circulating adiponectin levels and responsiveness to antihypertensive therapy in preeclampsia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira Daniela A, de Castro Ricardo N F, Palei Ana C, Cavalli Ricardo C, Sandrim Valéria C, Luizon Marcelo R
Аннотация
AIMS: We compared plasma adiponectin levels between patients with preeclampsia (PE) classified as responsive and nonresponsive to antihypertensive therapy; Moreover, we examined whether ADIPOQ SNPs rs17300539, rs266729,rs2241766, and rs1501299 and their haplotypes are associated with responsiveness to antihypertensive therapy, and whether they affect plasma adiponectin levels in 215 pregnant women with PE.
PATIENTS & METHODS: Genotypes for ADIPOQ SNPs were determined using TaqMan allelic discrimination assays, and circulating adiponectin concentrations were measured by ELISA.
RESULTS: Patients with PE classified as nonresponsive to antihypertensive therapy showed higher plasma adiponectin levels than responsive patients. The TG genotype of the rs2241766 SNP was more frequent in responsive patients with PE when compared to nonresponsive patients. Nonresponsive patients with PE carrying specific genotypes of the ADIPOQ SNPs rs17300539 (GG or GA+AA), rs266729 (CC), rs2241766(TT), and rs1501299 (GT+TT), respectively, as well as the 'G,C,T,G' and 'G,C,T,T' haplotypes showed higher plasma adiponectin levels than responsive patients with PE carrying the same genotypes/haplotypes.
CONCLUSIONS: Nonresponsive patients with PE showed higher plasma adiponectin levels than responsive patients, the TG genotype of the rs2241766 SNP was more frequent in the responsive patients with PE when compared to nonresponsive patients. Genotypes of rs17300539, rs266729, rs2241766, and rs1501299 SNPs and haplotypes may affect adiponectin levels in patients with PE classified as nonresponsive to antihypertensive therapy.
PATIENTS & METHODS: Genotypes for ADIPOQ SNPs were determined using TaqMan allelic discrimination assays, and circulating adiponectin concentrations were measured by ELISA.
RESULTS: Patients with PE classified as nonresponsive to antihypertensive therapy showed higher plasma adiponectin levels than responsive patients. The TG genotype of the rs2241766 SNP was more frequent in responsive patients with PE when compared to nonresponsive patients. Nonresponsive patients with PE carrying specific genotypes of the ADIPOQ SNPs rs17300539 (GG or GA+AA), rs266729 (CC), rs2241766(TT), and rs1501299 (GT+TT), respectively, as well as the 'G,C,T,G' and 'G,C,T,T' haplotypes showed higher plasma adiponectin levels than responsive patients with PE carrying the same genotypes/haplotypes.
CONCLUSIONS: Nonresponsive patients with PE showed higher plasma adiponectin levels than responsive patients, the TG genotype of the rs2241766 SNP was more frequent in the responsive patients with PE when compared to nonresponsive patients. Genotypes of rs17300539, rs266729, rs2241766, and rs1501299 SNPs and haplotypes may affect adiponectin levels in patients with PE classified as nonresponsive to antihypertensive therapy.